BiDil

BiDil is a brand name of hydralazine/isosorbide dinitrate, approved by the FDA in the following formulation(s):

BIDIL (hydralazine hydrochloride; isosorbide dinitrate - tablet; oral)

• 
  Manufacturer: ARBOR PHARMS INC
  
  Approval date: June 23, 2005
  
  Strength(s): 37.5MG;20MG ^[RLD]

Has a generic version of BiDil been approved?

No. There is currently no therapeutically equivalent version of BiDil available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of BiDil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
  Patent 6,465,463
  Issued: October 15, 2002
  Inventor(s): Jay N.; Cohn & Peter; Carson
  Assignee(s): NitroMed, Inc.
  The present invention provides methods or treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.
  
  Patent expiration dates:
  
  
  • September 8, 2020
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF HEART FAILURE
  
  



• 
  Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
  Patent 6,784,177
  Issued: August 31, 2004
  Inventor(s): Jay N.; Cohn & Peter; Carson
  Assignee(s): Nitro Med, Inc.
  The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension, and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.
  
  Patent expiration dates:
  
  
  • September 8, 2020
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF HEART FAILURE
  
  

See also...

• BiDil Consumer Information (Drugs.com)
• BiDil Consumer Information (Wolters Kluwer)
• BiDil Consumer Information (Cerner Multum)
• Isosorbide Dinitrate/Hydralazine Consumer Information (Wolters Kluwer)
• Hydralazine and isosorbide dinitrate Consumer Information (Cerner Multum)